Understanding early natural history to facilitate new clinical outcome assessments and trial design in children with friedreich ataxia (FRDA)

Active Grant Awarded

Award ID
R01FD008864
Recipient
Awarding agency
Obligated
$576,029

Award facts

Assistance listing
93.103 Food and Drug Administration Research
Completion date 4% complete
Funding agency
Office of Medical Products and Tobacco Food and Drug Administration, Department of Health and Human Services
Place of performance
Philadelphia, PA 19104, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services Food and Drug Administration awarded Grant R01FD008864 to The Children's Hospital of Philadelphia Research Institute on September 23, 2026, with $576,029 obligated under CFDA 93.103, Food and Drug Administration Research. The agency record lists the Office of Medical Products and Tobacco as an alternate name.

The award funds EARLY-FA, a study that will characterize the early natural history of Friedreich ataxia in 125 children and young adults and evaluate novel biomarkers and clinical outcome measures using digital health technologies. Its three specific aims are to examine associations between growth and pubertal development, body composition, and FRDA outcome measures; to identify blood or plasma biomarkers of clinical dysfunction that correlate with FRDA status and severity; and to identify ataxia performance outcome measures obtained by the AIMS digital health system. The study will also leverage data from the larger global natural history study, UNIFAI. The source describes a total study period of 24 months, with an ultimate completion date of August 31, 2030. Place of performance is Philadelphia, PA 19104, USA.

Description

Abstract
Friedreich ataxia (FRDA) is a rare genetic neurodegenerative condition that has onset in childhood with progression of symptoms leading to loss of ambulation, difficulty performing all activities of daily living, and early mortality. Individuals with an earlier onset of FRDA progress faster neurologically and have higher rates of cardiomyopathy, diabetes, scoliosis, visual loss and mortality. Initiation of treatment early in the course of the disease, prior to significant loss of function and degeneration is highly desirable. The difficulty in conducting clinical trials in children reflects multiple uncharacterized aspects of the early pathophysiology and pediatric phenotype in FRDA. The proposed research, early-FA, will characterize the early natural history of FRDA in 125 children and young adults with FRDA and evaluate novel biomarkers and clinical outcome measures using digital health technologies over a total period of 24 months. This study will also leverage data from a larger global natural history study: unifai. Early-FA will focus on three specific aims: • understanding the associations between growth and pubertal development, body composition and FRDA outcome measures, • identifying biomarkers of clinical dysfunction in blood or plasma that correlate with FRDA features like status and severity, and • identifying performance outcome measures of ataxia obtained by a novel digital health technologies: the aims systems outcomes from the early-FA study will help overcome some of the difficulties in conducting clinical trials in children with FRDA and advance the development of treatments for children with this disease.

Quick answers

Who received award R01FD008864?

R01FD008864 was awarded to The Children's Hospital Of Philadelphia by FDA Office of Acquisition and Grant Services (Food and Drug Administration) on September 23, 2026.

How much is award R01FD008864 worth?

$576,029 has been obligated on R01FD008864.

Which agency awarded R01FD008864?

FDA Office of Acquisition and Grant Services (Food and Drug Administration) awarded R01FD008864, with funding from Office of Medical Products and Tobacco (Food and Drug Administration).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award